Search Results
You are looking at 1 - 1 of 1 items for :
- Author: Peijie Hu x
- Metabolic Syndrome and Diabetes x
Search for other papers by Xue-Lian Zhang in
Google Scholar
PubMed
Search for other papers by Xinyi Zhao in
Google Scholar
PubMed
Department of Biomedical Engineering, Faculty of Engineering, The Hong Kong Polytechnic University, Hong Kong, China
Search for other papers by Yong Wu in
Google Scholar
PubMed
Search for other papers by Wen-qing Huang in
Google Scholar
PubMed
Department of Biomedical Engineering, Faculty of Engineering, The Hong Kong Polytechnic University, Hong Kong, China
Search for other papers by Jun-jiang Chen in
Google Scholar
PubMed
Search for other papers by Peijie Hu in
Google Scholar
PubMed
Search for other papers by Wei Liu in
Google Scholar
PubMed
Search for other papers by Yi-Wen Chen in
Google Scholar
PubMed
Search for other papers by Jin Hao in
Google Scholar
PubMed
Search for other papers by Rong-Rong Xie in
Google Scholar
PubMed
Search for other papers by Hsiao Chang Chan in
Google Scholar
PubMed
Search for other papers by Ye Chun Ruan in
Google Scholar
PubMed
Search for other papers by Hui Chen in
Google Scholar
PubMed
Search for other papers by Jinghui Guo in
Google Scholar
PubMed
Objective
The beneficial effect of angiotensin(1–7) (Ang(1–7)), via the activation of its receptor, MAS-1, has been noted in diabetes treatment; however, how Ang(1–7) or MAS-1 affects insulin secretion remains elusive and whether the endogenous level of Ang(1–7) or MAS-1 is altered in diabetic individuals remains unexplored. We recently identified an important role of cystic fibrosis transmembrane conductance regulator (CFTR), a cAMP-activated Cl− channel, in the regulation of insulin secretion. Here, we tested the possible involvement of CFTR in mediating Ang(1–7)’s effect on insulin secretion and measured the level of Ang(1–7), MAS-1 as well as CFTR in the blood of individuals with or without type 2 diabetes.
Methods
Ang(1–7)/MAS-1/CFTR pathway was determined by specific inhibitors, gene manipulation, Western blotting as well as insulin ELISA in a pancreatic β-cell line, RINm5F. Human blood samples were collected from 333 individuals with (n = 197) and without (n = 136) type 2 diabetes. Ang(1–7), MAS-1 and CFTR levels in the human blood were determined by ELISA.
Results
In RINm5F cells, Ang(1–7) induced intracellular cAMP increase, cAMP-response element binding protein (CREB) activation, enhanced CFTR expression and potentiated glucose-stimulated insulin secretion, which were abolished by a selective CFTR inhibitor, RNAi-knockdown of CFTR, or inhibition of MAS-1. In human subjects, the blood levels of MAS-1 and CFTR, but not Ang(1–7), were significantly higher in individuals with type 2 diabetes as compared to those in non-diabetic healthy subjects. In addition, blood levels of MAS-1 and CFTR were in significant positive correlation in type-2 diabetic but not non-diabetic subjects.
Conclusion
These results suggested that MAS-1 and CFTR as key players in mediating Ang(1–7)-promoted insulin secretion in pancreatic β-cells; MAS-1 and CFTR are positively correlated and both upregulated in type 2 diabetes.
